Linked Life Data

9649162

Source:http://linkedlifedata.com/resource/pubmed/id/9649162

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1998-7-13
pubmed:abstractText
Cisplatin-based combination chemotherapy is frequently used to treat patients with carcinoma of unknown primary site (CUPS). Response rates in the literature range from 12% to 26% and median survival from 5 to 7 months. The goal of this study was to evaluate the combination of carboplatin and prolonged oral etoposide in patients with CUPS, with the hope of minimizing toxicity but improving efficacy and convenience. Treatment consisted of carboplatin, 300 mg m(-2) on day 1, and oral etoposide 50 mg on days 1-20, every 4 weeks for up to nine cycles. A total of 33 patients were treated and all were evaluable for toxicity. Non-haematological toxicity was mild to moderate, with the exception of one case of grade 4 stomatitis. Grade 4 leucopenia was observed in eight (24%) patients and sepsis in four (12%), with two and possibly three treatment-related deaths. For the 26 patients evaluable for response, the response rate was 23% with responses lasting a median of 11 months (range 7-13 months), with one patient still responding at 12 months. An additional nine patients (35%) had stable disease. Median survival for all patients was 5.6 months (range 2 weeks to 33 months). The combination of carboplatin with prolonged oral etoposide has moderate activity similar to that of other platinum-based regimens and is a well tolerated, convenient, outpatient regimen. Dosing according to estimated creatinine clearance to achieve a carboplatin AUC of 6.0 mg ml(-1) min might have decreased the incidence of severe myelotoxicity without compromising the regimen's efficacy.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-1888154, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-1984833, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-2154857, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-2154858, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-2669133, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-2681557, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-2918334, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-3548315, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-3933808, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-4748282, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-6321006, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-7636553, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-7684858, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-8156538, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-8316270, http://linkedlifedata.com/resource/pubmed/commentcorrection/9649162-9196154
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
77
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2376-80
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
pubmed:affiliation
Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Ontario, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II